Intel (INTC) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The cardiovascular kidney and metabolic (CKM) health assessment and patient empowerment trial, officially titled “Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical Trial,” tests whether AI tools and remote monitoring can cut heart, kidney and diabetes risks in chronic disease patients. For investors, the study matters because it explores a scalable digital health model where Intel (INTC) is a key technology collaborator.
The trial’s main tools are the CHAPERONE AI platform and the CKMiq AI device, both designed to guide care for high risk heart, kidney and metabolic patients. The system uses chatbots, a digital copilot and sensor data to support treatment choices and improve long term quality of life and survival.
The study uses a randomized design that assigns eligible patients either to the AI supported CHAPERONE program or to usual care without added digital tools. There is no masking, so both patients and clinicians know who receives the AI intervention, and the primary goal is to see if this digital approach reduces disease progression, hospital visits and death.
The study was first submitted on 2026-02-04, marking the formal launch of the trial and its protocol. It is currently listed as recruiting, with a key recent update filed on 2026-02-10, signaling active operational progress and continued sponsor commitment.
While Intel is only one of several partners alongside Aventyn, Inc., Dignity Health and major universities, its role signals a push into AI powered healthcare infrastructure that could open new data and software revenue streams over time. If results show fewer readmissions and better outcomes, this could support Intel’s AI narrative versus rivals working on similar hospital and cloud based health platforms, though near term earnings impact is likely modest.
The study remains active and updated on the ClinicalTrials portal, where investors can monitor future milestones and published results.